<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35390475</PMID><DateCompleted><Year>2022</Year><Month>06</Month><Day>06</Day></DateCompleted><DateRevised><Year>2022</Year><Month>06</Month><Day>06</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1879-3177</ISSN><JournalIssue CitedMedium="Internet"><Volume>82</Volume><PubDate><Year>2022</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Toxicology in vitro : an international journal published in association with BIBRA</Title><ISOAbbreviation>Toxicol In Vitro</ISOAbbreviation></Journal><ArticleTitle>Cytotoxicity reduction by O-nicotinoylation of antiviral 6-benzylaminopurine ribonucleosides.</ArticleTitle><Pagination><StartPage>105355</StartPage><MedlinePgn>105355</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.tiv.2022.105355</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0887-2333(22)00052-2</ELocationID><Abstract><AbstractText>One of the promising approaches in the development of nucleoside prodrugs is to use the nucleoside analogs containing lipophilic biodegradable residues, which are cleaved to biologically active forms after metabolic transformations in the cell. The introduction of such fragments makes it possible to reduce the general toxicity of the drug candidate and increase its stability in the cell. In order to study the influence of biodegradable lipophilic groups on antiviral activity and cytotoxicity, in this work we synthesized N<sup>6</sup>-benzyl-2',3',5'-tri-O-nicotinoyl adenosine and N<sup>6</sup>-(3-fluorobenzyl)-2',3',5'-tri-O-nicotinoyl adenosine, derivatives of N<sup>6</sup>-benzyladenosine (BAR) and N<sup>6</sup>-(3-fluorobenzyl)adenosine (FBAR), which had previously shown prominent antiviral activity against human enterovirus EV-A71 but appeared to be cytotoxic. The obtained fully-O-nicotinoylated BAR and FBAR inhibited reproduction of EV-A71 strains BrCr and 46973 and manifested significantly lower cytotoxicity compared to non-protected compounds. In addition, we performed enzymatic hydrolysis of the fully-O-nicotinoylated FBAR in the presence of esterases (CalB and PLE) to investigate metabolic degradation of O-nicotinoylated compounds in cells. Both enzymes hydrolyzed the tested substrate to form the corresponding O-deprotected nucleoside that may suggest the role of hydrolase-type enzymes as general participants of metabolic activation of O-nicotinoylated prodrugs in different cells.</AbstractText><CopyrightInformation>Copyright Â© 2022 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Zenchenko</LastName><ForeName>Anastasia A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Oslovsky</LastName><ForeName>Vladimir E</ForeName><Initials>VE</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Varizhuk</LastName><ForeName>Irina V</ForeName><Initials>IV</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Karpova</LastName><ForeName>Evgenia V</ForeName><Initials>EV</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia; Sechenov First Moscow State Medical University, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Osolodkin</LastName><ForeName>Dmitry I</ForeName><Initials>DI</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia; Sechenov First Moscow State Medical University, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kozlovskaya</LastName><ForeName>Liubov I</ForeName><Initials>LI</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia; Sechenov First Moscow State Medical University, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ishmukhametov</LastName><ForeName>Aydar A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>FSASI "Chumakov FSC R&amp;D IBP RAS" (Institute of Poliomyelitis), Moscow 108819, Russia; Sechenov First Moscow State Medical University, Moscow 119991, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Drenichev</LastName><ForeName>Mikhail S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Engelhardt Institute of Molecular Biology, Moscow 119991, Russia. Electronic address: room517@eimb.ru.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Toxicol In Vitro</MedlineTA><NlmUniqueID>8712158</NlmUniqueID><ISSNLinking>0887-2333</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001593">Benzyl Compounds</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D009705">Nucleosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011355">Prodrugs</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011687">Purines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012263">Ribonucleosides</NameOfSubstance></Chemical><Chemical><RegistryNumber>K72T3FS567</RegistryNumber><NameOfSubstance UI="D000241">Adenosine</NameOfSubstance></Chemical><Chemical><RegistryNumber>KXG6A989PS</RegistryNumber><NameOfSubstance UI="C480551">benzylaminopurine</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000241" MajorTopicYN="N">Adenosine</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001593" MajorTopicYN="N">Benzyl Compounds</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029821" MajorTopicYN="Y">Enterovirus A, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009705" MajorTopicYN="N">Nucleosides</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011355" MajorTopicYN="Y">Prodrugs</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011687" MajorTopicYN="N">Purines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012263" MajorTopicYN="Y">Ribonucleosides</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">6-Benzylaminopurine ribonucleosides</Keyword><Keyword MajorTopicYN="N">Antiviral activity</Keyword><Keyword MajorTopicYN="N">Biodegradable lipophilic groups</Keyword><Keyword MajorTopicYN="N">Cytotoxicity reduction</Keyword><Keyword MajorTopicYN="N">Enterovirus EV-A71</Keyword><Keyword MajorTopicYN="N">O-Nicotinoylation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>1</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>6</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>7</Day><Hour>20</Hour><Minute>11</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35390475</ArticleId><ArticleId IdType="doi">10.1016/j.tiv.2022.105355</ArticleId><ArticleId IdType="pii">S0887-2333(22)00052-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle>